Evidence map›Paper›PMID 31164102›Full record

ArticleBMC cancer2019

Diffuse lichen planus-like keratoses and clinical pseudo-progression associated with avelumab treatment for Merkel cell carcinoma, a case report.

Michael A Cardis, Hong Jiang, Julius Strauss, James L Gulley, Isaac Brownell

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Risk of Lichen Sclerosus and Lichen Planus in Patients Receiving Immune Checkpoint Inhibitors.International journal of environmental research and public health · 2022
    Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Michael A CardisMedstar Washington Hospital Center/Georgetown University Hospital, Washington, DC, USA.
Hong JiangLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Julius StraussLaboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
James L GulleyGenitourinary Malignancies Branch, Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Isaac BrownellDermatology Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive, 12N240C, Bethesda, MD, 20892-1908, USA. isaac.brownell@nih.gov.ORCID http://orcid.org/0000-0002-0090-9914
National Institutes of Health · USGeorgetown University · US

Funding

Ipilimumab for treatment of advanced Merkel cell carcinomaZIABC011450 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI BROWNELL, ISAAC · 2012 to 2021
$1.0M
Intramural NIH HHS ZIA BC011450NCI NIH HHS ZIA BC 011450
6 · The paper itself

Abstract

backgroundAvelumab is an anti-programmed cell death ligand 1 (PD-L1) antibody approved for treatment of Merkel cell carcinoma (MCC) and locally advanced or metastatic urothelial carcinoma. It shares a similar side effect profile to other immune checkpoint inhibitors, including immune-related adverse reactions in the skin. These adverse skin reactions can present as a morbilliform exanthem, lichenoid dermatitis, vitiligo, autoimmune bullous disorder, among others. CASE PRESENTATION: We describe a patient with advanced MCC successfully treated with avelumab who developed acute onset diffuse lichen planus-like keratoses (LPLK) at sites of existing seborrheic keratoses (SK) and lentigines. Histopathology of an affected SK revealed papillomatous epidermal hyperplasia with lichenoid interface changes, numerous dyskeratotic keratinocytes and intermittent hypergranulosis. The findings resembled lichen planus (LP) arising in an SK. Onset of the skin symptoms corresponded with an inflammatory cancer response (clinical pseudo-progression), and the eruption improved as overall tumor burden decreased. The patient's pruritus was treated with topical steroids and cyrotherapy for individual symptomatic lesions.

conclusionDiffuse LPLK is a distinct immune-related reaction pattern associated with PD-L1/PD-1 checkpoint blockade. This is an important side effect to be aware of as LPLK frequently mimic keratinocytic neoplasms. Further observation is needed to assess the prevalence and significance of this immune therapy-associated adverse reaction.

Indexed as

AgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsB7-H1 AntigenCarcinoma, Merkel CellCryotherapyDisease ProgressionGlucocorticoidsHumansKeratosisLichen PlanusMalePositron Emission Tomography Computed TomographyProgrammed Cell Death 1 ReceptorSkin NeoplasmsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsavelumabB7-H1 AntigenCD274 protein, humanGlucocorticoidsPDCD1 protein, humanProgrammed Cell Death 1 ReceptorTriamcinoloneDrug reactionsImmune checkpointImmunologyLichen planus-like keratosisMerkel cell

Identifiers

PMID31164102
PMCPMC6549366
OpenAlexW2948574482

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.